SELLAS Life Sciences to Host Key Opinion Leader Webinar on
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University of Alabama...
Source: globenewswire.com
Page 16 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sciences Group Today - Breaking & Trending Today
Dianthus Therapeutics Strengthens Leadership Team with Appointment of Susan Kalled, Ph.D., as Chief Scientific Officer
/PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced...
Source: prnewswire.com
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
13.12.2022 - GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose Levels in Both Acute Myeloid Leukemia and Lymphoma Patients No Dose Limiting Toxicities Observed at ... Seite 1
Source: wallstreet-online.de
Tiny, Menacing Microclots May Explain Long COVID's Symptoms
Some long COVID researchers have suspected smaller, less obvious blood clots may be causing many of the puzzling symptoms reported by patients who have lasting effects of the virus.
Source: medscape.com
SELLAS Life Sciences CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight Participating Research Institutions.
Source: pressreleasepoint.com